High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.

J Transl Med · 2011 · PMC3258225 · PMID 22188900

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

While these effects are highly significant, strategies to prolong the effects of sorafenib and other VEGFR TKI targeted agents are important as tumors typically develop resistance to therapy within 5-11 months.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.